Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03379532 · ClinicalTrials.gov registry record · NA

BCI-controlled NMES in Subacute Stroke

A NA study of Stroke, sponsored by University Hospital, Geneva.

Completed
Registry status
NA
Development phase
31
Enrollment target
2
Study locations

NCT03379532 is a NA study of Stroke that has completed, run by University Hospital, Geneva. The registered enrollment target is 31 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03379532, a NA study of Stroke, has completed, sponsored by University Hospital, Geneva.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
2
Study locations

Study Summary

Stroke patients with severe upper limb movement deficits have limited treatment options and often remain severely handicapped at the chronic stage. Recent findings have suggested that poor motor recovery can be due to severe damage of the cortico-spinal tract (CST), the neural fibres connecting the movement regions of the brain to the spinal cord. Hence, to improve recovery of upper limb movements it will be crucial to re-establish and strengthen CST projections. Recent studies provided evidence that closed-loop brain computer interface-driven electrical stimulation of the paretic muscles can induce clinically important and lasting recovery of upper limb function, even in patients with chronic, severe motor affection. In this treatment approach, movement intentions of the patients are detected with electroencephalography and real-time analyses. This triggers an electrical stimulation of affected upper limb muscles. In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to voluntary activation of primary motor cortex, as detected by a brain-computer interface (BCI), can help restore CST projections. This might improve recovery of patients with severe upper limb movement deficits. Treatment will be started within the first 8 weeks after stroke onset.

Conditions Studied

Interventions

  • DEVICE BCI-NMES
  • DEVICE Sham-NMES

Study Locations (2)

Texas

  • University of Austin - Austin

Canton of Geneva

  • Division of Neurorehabilitation, University Hospital of Geneva - Geneva

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2018-01-26
Est. Completion 2024-04-30
Phase NA

Sponsor

University Hospital, Geneva

4 total trials

What the Registry Record Tells You About NCT03379532

The ClinicalTrials.gov registry entry for NCT03379532 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is University Hospital, Geneva, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which BCI-NMES is the first listed.

NCT03379532 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Canton of Geneva.

Frequently Asked Questions

What is clinical trial NCT03379532 about?

NCT03379532 is a clinical study titled "BCI-controlled NMES in Subacute Stroke". Stroke patients with severe upper limb movement deficits have limited treatment options and often remain severely handicapped at the chronic stage. Recent findings have suggested that poor motor recovery can be due to severe damage of the cortico-spinal tract (CST), the neural fibres connecting the...

What is the current status of trial NCT03379532?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2018-01-26. Estimated completion is 2024-04-30.

What conditions does trial NCT03379532 study?

This clinical trial studies the following conditions: Stroke.

What interventions are being tested in trial NCT03379532?

The interventions under investigation include: BCI-NMES (DEVICE), Sham-NMES (DEVICE).

Who is sponsoring clinical trial NCT03379532?

This trial is sponsored by University Hospital, Geneva, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03379532 being conducted?

This trial has 2 study locations across Texas, Canton of Geneva. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.